Phillip Securities Research Maintains Neutral Stance with Reduced Target Price
Raffles Medical Group Ltd, a Singapore-based healthcare services provider operating hospitals, medical centers, and transitional care facilities across Singapore and Greater China, is experiencing significant headwinds as lower-cost alternatives pressure its traditional business model. Phillip Securities Research has maintained its NEUTRAL recommendation while lowering the DCF target price to S$0.92 from the previous S$1.02.
Disappointing Half-Year Performance
The company’s 1H26 results fell short of expectations, with revenue and adjusted profit after tax and minority interests (PATMI) representing only 44% and 40% of full-year estimates respectively. Adjusted PATMI declined 18% year-over-year to S$29 million, while revenue dropped 7% to S$353 million, primarily due to weakness in the transitional care facility segment.
Healthcare services revenue contracted sharply by 17% year-over-year to S$112 million, driven by reduced patient load from TCF operations. The expansion of public hospital beds has significantly impacted TCF utilization rates, creating substantial operational challenges for this high-fixed-cost segment.
Positive Developments Amid Challenges
Despite the overall weak performance, Raffles Medical’s hospital services demonstrated resilience with profit before tax growing 11% year-over-year to S$19.7 million in 1H26. This improvement stems from higher revenue intensity surgical cases and moderate price increases, indicating the company’s ability to maintain margins in its core hospital operations through strategic pricing and case mix optimization.
Significant Operational Headwinds
The transitional care facility operations present the most significant drag on performance. While TCF contribution figures are not separately disclosed, the segment’s high fixed costs in wages and rental expenses led to a dramatic 38% year-over-year plunge in earnings to S$15.6 million. The substantial fixed cost structure makes this segment particularly vulnerable to utilisation pressures from expanded public hospital capacity.
Outlook and Strategic Challenges
Phillip Securities Research has reduced FY26e adjusted PATMI estimates by 10% to S$65.4 million, reflecting 5% lower revenue projections. The challenging operating environment persists as patient volumes face pressure from cheaper alternatives in overseas markets, particularly Malaysia, and expanded public hospital options. Additionally, private insurers continue pressuring revenue intensity improvements, while China operations show growth potential despite ongoing regulatory uncertainties.
This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
This advertisement has not been reviewed by the Monetary Authority of Singapore.
